Simple synthesis of biocompatible biotinylated porous hexagonal ZnO nanodisc for targeted doxorubicin delivery against breast cancer cell: In vitro and in vivo cytotoxic potential

•Synthesis and physicochemical characterizations of biotinylated porous hexagonal zinc oxide nanodisc.•Drug (doxorubicin) loading and release profile study.•Targeted delivery of doxorubicin loaded biotinylated porous hexagonal zinc oxide nanodisc against breast cancer cell: in vitro and in vivo.•Mod...

Full description

Saved in:
Bibliographic Details
Published in:Colloids and surfaces, B, Biointerfaces Vol. 133; pp. 88 - 98
Main Authors: Patra, Prasun, Mitra, Shouvik, Das Gupta, Amarto, Pradhan, Saheli, Bhattacharya, Saurav, Ahir, Manisha, Mukherjee, Sudeshna, Sarkar, Sampad, Roy, Subhrodeb, Chattopadhyay, Sreya, Adhikary, Arghya, Goswami, Arunava, Chattopadhyay, Dhrubajyoti
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01-09-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Synthesis and physicochemical characterizations of biotinylated porous hexagonal zinc oxide nanodisc.•Drug (doxorubicin) loading and release profile study.•Targeted delivery of doxorubicin loaded biotinylated porous hexagonal zinc oxide nanodisc against breast cancer cell: in vitro and in vivo.•Mode of action study of this nanocargo against breast cancer cells.•Biocompatibility study: in vitro and in vivo. Targeted drug delivery with porous materials features great promise as improved therapeutic potential for treatment of various diseases. In the present study we have attempted a microwave synthesis of porous hexagonal nanodisc of zinc oxide (PZHD) for the first time and its subsequent targeted delivery to breast cancer cells, MCF7. PZHD has been fabricated suitably with 3-aminopropyltriethoxysilane to impart additional stability and surface amines to anchor site directing ligand NHS-biotin. Biotinylated scaffold showed targeted delivery of anticancer drug doxorubicin and pH triggered release to MCF 7 cells with preferential distribution on specified domain. A detailed in vitro cytotoxicity study was associated with it to evaluate the mode of action of Dox loaded PZHD on MCF-7 cells by means of cell cycle analysis, apoptosis assays, Western blot and immuno-fluorescence image analysis. The efficacy of the Dox loaded PZHD was further validated from our in vivo tumor regression studies. Finally, the whole study has been supported by in vitro and in vivo bio-safety studies which also signified its biocompatibility with real time applications. To the best of our knowledge this is the first effort to use biotinylated PZHD for targeted delivery of doxorubicin within MCF 7 cells with a detailed study of its mechanistic application. This study might thus hold future prospects for therapeutic intervention for treatment of cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0927-7765
1873-4367
DOI:10.1016/j.colsurfb.2015.05.052